Literature DB >> 16778309

Pathophysiology of visceral leishmaniasis - some recent concepts.

Nancy Malla1, R C Mahajan.   

Abstract

Visceral leishmaniasis is characterized by diversity and complexity of clinical manifestations ranging from asymptomatic infection to life threatening illness. Experimental evidence and clinical studies indicate multifaceted role of various factors leading to parasite survival and multiplication. In early stage of infection, generation of reactive oxygen and nitrogen intermediates play significant role in curtailing the parasite multiplication while in later phase on one hand, hepatic resistance is expressed by the dominant role played by nitric oxide synthase (NOS)-2 gene regulation and on the other hand, production of inhibitors of NOS-2 gene expression, interleukin 10 (IL-10) and transforming growth factor beta (TGFbeta) correlate well with reduced parasite killing. The hepatic infection is usually self-limiting due to production of multiple cytokine responses including moderate level of tumour necrosis factor (TNF) while in spleen excess TNF mediates destructive pathology. CD8+ T cells appear to play multiple roles comprising both cytotoxic activity and secretion of cytokines and chemokines. Capacity to produce ThI cytokines is associated with asymptomatic or subclinical self-healing infection. However, in symptomatic patients, Th I cytokine production is not depressed but there appears to be unresponsiveness to the stimuli of these cytokines. Experimental evidences indicate genetic basis for such a phenomenon.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778309

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  10 in total

Review 1.  Role of chemokines in regulation of immunity against leishmaniasis.

Authors:  Steve Oghumu; Claudio M Lezama-Dávila; Angelica P Isaac-Márquez; Abhay R Satoskar
Journal:  Exp Parasitol       Date:  2010-03-03       Impact factor: 2.011

2.  Efficacy and safety of single-dose liposomal amphotericin B in patients with visceral leishmaniasis in Bangladesh: a real-life experience.

Authors:  Md Rezaul Ekram; Mohammad Robed Amin; Mohammad Jahid Hasan; Md Abdullah Saeed Khan; Rajib Nath; Pranab Kumar Mallik; Alex Lister; Monjur Rahman
Journal:  J Parasit Dis       Date:  2021-03-23

3.  Visceral leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of risk factors and trends.

Authors:  Stanislaw Gorski; Simon M Collin; Koert Ritmeijer; Kees Keus; Francis Gatluak; Marius Mueller; Robert N Davidson
Journal:  PLoS Negl Trop Dis       Date:  2010-06-08

4.  A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model.

Authors:  Ellen K Wasan; Pavel Gershkovich; Jinying Zhao; Xiaohua Zhu; Karl Werbovetz; Richard R Tidwell; John G Clement; Sheila J Thornton; Kishor M Wasan
Journal:  PLoS Negl Trop Dis       Date:  2010-12-07

5.  Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules.

Authors:  Shalini Asthana; Anil K Jaiswal; Pramod K Gupta; Vivek K Pawar; Anuradha Dube; Manish K Chourasia
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

Review 6.  The pathogenicity and virulence of Leishmania - interplay of virulence factors with host defenses.

Authors:  Anand Kumar Gupta; Sonali Das; Mohd Kamran; Sarfaraz Ahmad Ejazi; Nahid Ali
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

7.  Effectiveness and safety of short course liposomal amphotericin B (AmBisome) as first line treatment for visceral leishmaniasis in Bangladesh.

Authors:  Emiliano Lucero; Simon M Collin; Sujit Gomes; Fatima Akter; Asaduzzam Asad; Asish Kumar Das; Koert Ritmeijer
Journal:  PLoS Negl Trop Dis       Date:  2015-04-02

8.  Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.

Authors:  Andrew A Voak; Joseph F Standing; Nuno Sepúlveda; Andy Harris; Simon L Croft; Karin Seifert
Journal:  J Antimicrob Chemother       Date:  2018-05-01       Impact factor: 5.790

9.  Assessment of liver function test and associated factors among visceral leishmaniasis patients attending university of gondar leishmaniasis research and treatment center, Northwest Ethiopia.

Authors:  Hiwot Tezera Endale; Tiget Ayelgn Mengstie; Dilargachew Dessie Dawit; Rezika Mohammed; Gashaw Dessie; Kibur Hunie Tesfa
Journal:  PLoS One       Date:  2021-11-19       Impact factor: 3.240

Review 10.  Vulnerabilities to and the Socioeconomic and Psychosocial Impacts of the Leishmaniases: A Review.

Authors:  Grace Grifferty; Hugh Shirley; Jamie McGloin; Jorja Kahn; Adrienne Orriols; Richard Wamai
Journal:  Res Rep Trop Med       Date:  2021-06-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.